Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##SCROLLER_ITEMS_FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##SCROLLER_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##SCROLLER_ITEMS_FULL_TITLE##

Unique Dutch collaborative effort to identify FH patients

3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##SCROLLER_ITEMS_FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##SCROLLER_ITEMS_FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

FH in Europe: Need for a registry

3' education - Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##SCROLLER_ITEMS_FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##SCROLLER_ITEMS_FULL_TITLE##

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.

Lp(a) meeting The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.

Blood donor screening as potential strategy for FH screening

Literature - June 25, 2019 - Jackson CL et al. - JAMA Cardiol 2019
In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

In >1 million blood donors, the prevalence of FH was similar to the estimated prevalence of FH in the general population. This suggests that donor screening may represent a new approach for FH screening and intervention.

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD
Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

Elevated Lp(a) levels and apo(a) production in response to statins

Literature - June 12, 2019 - Tsimikas S et al. - Eur Heart J 2019

A meta-analysis showed significantly elevated Lp(a) levels with statin therapy and a cell culture study demonstrated increased apo(a) production after statin treatment, which possibly contributes to the residual CV risk in subjects on statins.

Almost 1 in 10 of young adults with MI has clinically defined FH

Literature - June 6, 2019 - Singh A et al., - J Am Coll Cardiol. 2019

9% Of adults who experience MI before 50 years of age, have probable or definite FH. Statin therapy is often suboptimal and so are LDL-c levels at 1 year post-MI.

Failure to identify FH results in worse survival compared with people with an FH diagnosis

News - May 31, 2019
A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

Greater benefit of statin therapy in those with inherited high LDL, suggests 4S

News - May 28, 2019
An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

Homozygous FH in children is clinically more diverse than clinical diagnostic criteria suggest

Literature - May 20, 2019 - Luirink IK et al., - J Clin Lipidol. 2019

LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.

FDA expands indication for PCSK9 inhibitor to prevent major CV events in adults with CVD

News - May 6, 2019

The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.

Safety of cholesterol biosynthesis inhibitor in high CV risk patients

Literature - Apr. 9, 2019 - Ray KK et al. - NEJM 2019

Safety of bempedoic acid was studied over a 1-year period in the CLEAR Harmony trial, which enrolled high CV risk patients.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

CME accredited E-Learning

Online-CME - This course consists of 4 separate lectures
This course consists of 4 separate lectures

CME accredited course focussed on the role of PCSK9 inhibitors in the management of patients at increased CV risk. Member registration (free) is needed to enroll in this course